ConnectOnCall Data Breach

Notice of Data Privacy Incident
Increase Text
Call +18003316634 Request an Appointment Visit Menu

Our Clinical Trials

The specialists of Mid Atlantic Retina have been principal investigators of nearly all the major clinical trials in retina, and for several, we are the only center involved nationwide. We are in the forefront of research efforts, participating in several clinical trials investigating new forms of treatment for macular degeneration, diabetic retinopathy, and a variety of other retinal conditions.

All clinical trials have guidelines (inclusion criteria) which explain who can participate. Our care team can help you identify clinical trials for which you may be eligible, how long you may be in the study, and what to expect during your experience on the study so you can make an informed decision about participating. Your decision to enroll is entirely yours, and you can withdraw at any time if you change your mind.

Participation in all clinical trials is voluntary and patients may choose to withdraw from any study at any time. Most of our clinical trials are sponsored by the federally-funded National Institutes of Health (NIH) or pharmaceutical and biotechnology companies. ClinicalTrials.Gov lists these and other clinical trials.

Available Clinical Trials

Below is a list of our studies that are currently enrolling new patients.
Click on the name of the study to be directed to each study-specific page on clinicaltrials.gov

Diabetic Macular Edema

  • EyeBiotech BRUNELLO
    • A randomized, double-masked, multi-center, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal eye103 compared with intravitreal ranibizumab (0.5mg) in participants with diabetic macular edema.
  • Kyowa Kirin 4951-003
    • A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients with Diabetic Macular Edema
  • Genentech THAMES GR43828
    • A phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of RO7446603 administered alone or in combination with Aflibercept or Faricimab in patients with diabetic macular edema.
  • Genentech
    • A phase 1, multipart, multicenter study to investigate the safety, tolerability, pharamcokinetics and pharamcodynamics of RO7497372 following intravitreal administration in participants with diabetic macular edam (Part 1 non-randomized, open-label, multiple ascending dose; Part 2 randomized, double-masked)

Geographic Atrophy (Advanced Dry AMD)

  • Apellis GARLAND
    • A prospective, multicenter, open-label, observational phase 4 study to evaluate real-world safety, tolerability, and treatment patterns of pegcetacoplan (Syfovre) in patients with geographic atrophy secondary to age-related macular degeneration
  • Lineage/Genentech GR44251 JUMPER
    • A phase 2A multicenter, open-label, single-arm study to optimize subretinal surgical delivery and to evaluate safety and activity of Opregen in patients with geographic atrophy secondary to age-related macular degeneration.
  • Belite Bio PHOENIX
    • Phase 3, Multicenter, RandOmized, Double-masked, Placebo-Controlled Study of TInlarebant to Explore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
  • Stealth Biotherapeutics RENEW
    • ReNEW: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration (Dry AMD)
  • Astellas (AIRM)
    • A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration
  • ANX007 GA_002 (PPD)
    • A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)
  • Regeneron (R3918-AMD-2326) SIENA
    • Multicenter, randomized, double-masked, placebo-controlled phase 3 study of the efficacy, safety, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with geographic atrophy secondary to age-related macular degeneration
  • Boehringer Ingelheim JADE
    • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebocontrolled, dose-finding study to evaluate the efficacy and safety of BI 1584862
  • Boehringer Ingelheim VERDANT
    • Randomized, double-masked, active-controlled, multi-center study to evaluate efficacy and safety of two regimens of intravitreal BI771716 against pegcetacoplan in participants with geographic atrophy secondary to age-related macular degeneration (VERDANT Trial)

Wet Macular Degeneration

  • RegenxBio ATMOSPHERE
    • A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
  • Vanotech
    • A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration
  • REGENXBIO AAVIATE
    • A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
  • RegenxBio ASCENT
    • A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
  • DRCR Protocol AO
    • Home OCT-Guided Treatment versus Treat and Extend for the Management of 1 Neovascular AMD (Protocol AO)
  • Eyepoint (LUCIA)
    • A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
  • Roche/Genentech BURGUNDY
    • A three-part, phase 1 study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO7250284 following intravitreal administration of multiple ascending doses and sustained delivery from the port delivery system in patients with neovascular age-related macular degeneration (BURGUNDY)
  • Alcon NOVA1
    • A Phase 1/2 Two-Stage Dose Escalation and Randomized Parallel Group Study to Evaluate the Safety, Preliminary Treatment Effects, and Durability of AR-14034 Sustained Release Implant Compared to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment in Participants with Neovascular Age-Related Macular Degeneration (NOVA-1)
  • Adverum
    • A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration
  • 4DMT FRONT1
    • A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1)
  • Sanofi
    • A Phase 1/2 dose escalation and dose expansion study to evaluate the safety, tolerability, and efficacy of one-time intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration

Retinitis Pigmentosa

  • AGTC Beacon
    • A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

Stargardt Disease

  • Belite Bio DRAGON
    • A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects with Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects with Stargardt Disease

Uveitis

  • Priovant CLARITY PVT-2201-303
    • A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active, Non-Infectious Intermediate-, Posterior-, and Panuveitis